Literature DB >> 16633052

Predicting the Crohn's disease activity index from the Harvey-Bradshaw Index.

William R Best1.   

Abstract

BACKGROUND: The Crohn's Disease Activity Index (CDAI) was developed in the 1970s to assess the degree of illness in individuals with Crohn's disease and has since been used widely in clinical trials of the condition. The Harvey-Bradshaw Index (HBI) is a simplification of the CDAI, designed to make data collection and computation easier. It is purported, on the basis of a 0.93 correlation coefficient, to give "essentially the same information." However, correlation is an incomplete way to assess sameness, and this study aimed to develop a method for predicting CDAI from HBI values, including relevant prediction limits.
MATERIALS AND METHODS: Data used in developing both indexes were combined. Single visits of 224 patients with Crohn's disease were plotted on a scattergram. HBI values seen were integers from 0 through 19. Mean and standard deviation of CDAI were determined for each HBI value that included a sufficient number of patients. Standard deviation of CDAI showed a linear increase with increasing HBI. Therefore, regression of CDAI on HBI was weighted on the inverse of the estimated CDAI standard deviation.
RESULTS: Regression predicted a 27-CDAI-unit increase for each HBI unit. Calculated 95% prediction limits were almost straight, diverging lines, bracketing 95% of observations. A table gives central tendency and 95% prediction limits of CDAI for any HBI, as well as key clinical benchmarks.
CONCLUSIONS: There is a good but far from perfect relationship between CDAI and HBI. CDAI is preferred for clinical trials; HBI is easier to use.

Entities:  

Mesh:

Year:  2006        PMID: 16633052     DOI: 10.1097/01.MIB.0000215091.77492.2a

Source DB:  PubMed          Journal:  Inflamm Bowel Dis        ISSN: 1078-0998            Impact factor:   5.325


  59 in total

1.  Day-by-Day Management of the Inpatient With Moderate to Severe Inflammatory Bowel Disease.

Authors:  Sara Lewin; Fernando S Velayos
Journal:  Gastroenterol Hepatol (N Y)       Date:  2020-09

2.  The use of 5-aminosalicylate for patients with Crohn's disease in a prospective European inception cohort with 5 years follow-up - an Epi-IBD study.

Authors:  Johan Burisch; Daniel Bergemalm; Jonas Halfvarson; Viktor Domislovic; Zeljko Krznaric; Adrian Goldis; Jens F Dahlerup; Pia Oksanen; Pekka Collin; Luisa de Castro; Vicent Hernandez; Svetlana Turcan; Elena Belousova; Renata D'Incà; Alessandro Sartini; Daniela Valpiani; Martina Giannotta; Ravi Misra; Naila Arebi; Dana Duricova; Martin Bortlik; Kelly Gatt; Pierre Ellul; Natalia Pedersen; Jens Kjeldsen; Karina W Andersen; Vibeke Andersen; Konstantinos H Katsanos; Dimitrios K Christodoulou; Shaji Sebastian; Luisa Barros; Fernando Magro; Jóngerð Mm Midjord; Kári R Nielsen; Riina Salupere; Hendrika Al Kievit; Gediminas Kiudelis; Juozas Kupčinskas; Mathurin Fumery; Corinne Gower-Rousseau; Ioannis P Kaimakliotis; Doron Schwartz; Selwyn Odes; Laszlo Lakatos; Peter L Lakatos; Ebbe Langholz; Pia Munkholm
Journal:  United European Gastroenterol J       Date:  2020-07-26       Impact factor: 4.623

3.  High prevalence of vitamin A deficiency in Crohn's disease patients according to serum retinol levels and the relative dose-response test.

Authors:  Márcia Soares-Mota; Tianny A Silva; Luanda M Gomes; Marco A S Pinto; Laura M C Mendonça; Maria Lúcia F Farias; Tiago Nunes; Andrea Ramalho; Cyrla Zaltman
Journal:  World J Gastroenterol       Date:  2015-02-07       Impact factor: 5.742

4.  Health-related quality of life in inflammatory bowel disease in a Danish population-based inception cohort.

Authors:  Lea K Christiansen; Bobby Lo; Flemming Bendtsen; Ida Vind; Marianne K Vester-Andersen; Johan Burisch
Journal:  United European Gastroenterol J       Date:  2019-05-17       Impact factor: 4.623

5.  Accuracy of Rapid Fecal Calprotectin Test in Monitoring Inflammatory Bowel Diseases Under Treatment with TNFα Antagonists.

Authors:  Antonio Tursi; Walter Elisei; Marcello Picchio; GianMarco Giorgetti; Giovanni Brandimarte
Journal:  Dig Dis Sci       Date:  2014-12-02       Impact factor: 3.199

6.  Higher Mucosal Healing with Tumor Necrosis Factor Inhibitors in Combination with Thiopurines Compared to Methotrexate in Crohn's Disease.

Authors:  Abhinav Vasudevan; Ajay Raghunath; Shane Anthony; Cian Scanlon; Miles P Sparrow; Peter R Gibson; Daniel R van Langenberg
Journal:  Dig Dis Sci       Date:  2018-12-17       Impact factor: 3.199

7.  Intima-media thickness of the common carotid artery is not significantly higher in Crohn's disease patients compared to healthy population.

Authors:  Efrat Broide; Andrei Schopan; Michael Zaretsky; Nimrod Alain Kimchi; Michael Shapiro; Eitan Scapa
Journal:  Dig Dis Sci       Date:  2010-05-01       Impact factor: 3.199

8.  Plasma long noncoding RNA expression profile identified by microarray in patients with Crohn's disease.

Authors:  Dong Chen; Jiang Liu; Hui-Ying Zhao; Yi-Peng Chen; Zun Xiang; Xi Jin
Journal:  World J Gastroenterol       Date:  2016-05-21       Impact factor: 5.742

Review 9.  Crohn's disease.

Authors:  Giulia Roda; Siew Chien Ng; Paulo Gustavo Kotze; Marjorie Argollo; Remo Panaccione; Antonino Spinelli; Arthur Kaser; Laurent Peyrin-Biroulet; Silvio Danese
Journal:  Nat Rev Dis Primers       Date:  2020-04-02       Impact factor: 52.329

10.  Detection of galectin-3 in patients with inflammatory bowel diseases: new serum marker of active forms of IBD?

Authors:  Lenka Frol'ová; Karel Smetana; Dana Borovská; Andrea Kitanovicová; Klára Klimesová; Ivana Janatková; Karin Malícková; Milan Lukás; Pavel Drastich; Zdenek Benes; Ludmila Tucková; Joachim C Manning; Sabine André; Hans-Joachim Gabius; Helena Tlaskalová-Hogenová
Journal:  Inflamm Res       Date:  2009-03-07       Impact factor: 4.575

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.